Synageva BioPharma Corp., of Lexington, Mass., said a 12-week Phase I/II extension study data published in Hepatology showed that for seven patients with lysosomal acid lipase deficiency who completed dosing with sebelipase alfa, mean percent decreases for ALT and AST from both the initial baseline to week 12 were 52 percent and 36 percent, respectively (p < 0.05 for both).
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter